137 related articles for article (PubMed ID: 16029146)
1. Receptor tyrosine kinases as targets for anticancer therapeutics.
Carlomagno F; Santoro M
Curr Med Chem; 2005; 12(15):1773-81. PubMed ID: 16029146
[TBL] [Abstract][Full Text] [Related]
2. Receptor tyrosine kinases and targeted cancer therapeutics.
Takeuchi K; Ito F
Biol Pharm Bull; 2011; 34(12):1774-80. PubMed ID: 22130229
[TBL] [Abstract][Full Text] [Related]
3. Gastrointestinal stromal tumours and their response to treatment with the tyrosine kinase inhibitor imatinib.
Mechtersheimer G; Egerer G; Hensel M; Rieker RJ; Libicher M; Lehnert T; Penzel R
Virchows Arch; 2004 Feb; 444(2):108-18. PubMed ID: 14735360
[TBL] [Abstract][Full Text] [Related]
4. Radiolabelled receptor-tyrosine-kinase targeting drugs for patient stratification and monitoring of therapy response: prospects and pitfalls.
Tolmachev V; Stone-Elander S; Orlova A
Lancet Oncol; 2010 Oct; 11(10):992-1000. PubMed ID: 20667780
[TBL] [Abstract][Full Text] [Related]
5. Receptor tyrosine kinases as targets for anticancer drugs.
Zwick E; Bange J; Ullrich A
Trends Mol Med; 2002 Jan; 8(1):17-23. PubMed ID: 11796262
[TBL] [Abstract][Full Text] [Related]
6. Receptor tyrosine kinases as target for anti-cancer therapy.
Brunelleschi S; Penengo L; Santoro MM; Gaudino G
Curr Pharm Des; 2002; 8(22):1959-72. PubMed ID: 12171522
[TBL] [Abstract][Full Text] [Related]
7. Oligonucleotide aptamers against tyrosine kinase receptors: Prospect for anticancer applications.
Camorani S; Crescenzi E; Fedele M; Cerchia L
Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):263-277. PubMed ID: 29574128
[TBL] [Abstract][Full Text] [Related]
8. Receptor Tyrosine Kinase-Targeted Cancer Therapy.
Yamaoka T; Kusumoto S; Ando K; Ohba M; Ohmori T
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30404198
[TBL] [Abstract][Full Text] [Related]
9. Receptor tyrosine kinase inhibitors: molecularly targeted drugs for veterinary cancer therapy.
Bavcar S; Argyle DJ
Vet Comp Oncol; 2012 Sep; 10(3):163-73. PubMed ID: 22882485
[TBL] [Abstract][Full Text] [Related]
10. Forthcoming receptor tyrosine kinase inhibitors.
Choong NW; Cohen EE
Expert Opin Ther Targets; 2006 Dec; 10(6):793-7. PubMed ID: 17105367
[TBL] [Abstract][Full Text] [Related]
11. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
Faivre S; Djelloul S; Raymond E
Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
[TBL] [Abstract][Full Text] [Related]
12. Progress in cancer therapy targeting c-Met signaling pathway.
Jung KH; Park BH; Hong SS
Arch Pharm Res; 2012 Mar; 35(4):595-604. PubMed ID: 22553051
[TBL] [Abstract][Full Text] [Related]
13. Structural studies of full-length receptor tyrosine kinases and their implications for drug design.
Bajinting A; Ng HL
Adv Protein Chem Struct Biol; 2021; 124():311-336. PubMed ID: 33632469
[TBL] [Abstract][Full Text] [Related]
14. [Antineoplastic agents targeting tyrosine kinases].
Guren TK; Christoffersen T; Thoresen GH; Wisløff F; Dajani O; Tveit KM
Tidsskr Nor Laegeforen; 2005 Nov; 125(22):3115-9. PubMed ID: 16299568
[TBL] [Abstract][Full Text] [Related]
15. Tyrosine kinase inhibitors targeted to the epidermal growth factor receptor subfamily: role as anticancer agents.
Noonberg SB; Benz CC
Drugs; 2000 Apr; 59(4):753-67. PubMed ID: 10804033
[TBL] [Abstract][Full Text] [Related]
16. Flavonoids as RTK inhibitors and potential anticancer agents.
Teillet F; Boumendjel A; Boutonnat J; Ronot X
Med Res Rev; 2008 Sep; 28(5):715-45. PubMed ID: 18080331
[TBL] [Abstract][Full Text] [Related]
17. Multitarget drugs: the present and the future of cancer therapy.
Petrelli A; Valabrega G
Expert Opin Pharmacother; 2009 Mar; 10(4):589-600. PubMed ID: 19284362
[TBL] [Abstract][Full Text] [Related]
18. Tyrosine kinase receptors as attractive targets of cancer therapy.
Bennasroune A; Gardin A; Aunis D; Crémel G; Hubert P
Crit Rev Oncol Hematol; 2004 Apr; 50(1):23-38. PubMed ID: 15094157
[TBL] [Abstract][Full Text] [Related]
19. Small tyrosine kinase inhibitors as key molecules in the expression of metalloproteinases by solid tumors.
Stahtea XN; Kousidou OCh; Roussidis AE; Tzanakakis GN; Karamanos NK
Connect Tissue Res; 2008; 49(3):211-4. PubMed ID: 18661345
[TBL] [Abstract][Full Text] [Related]
20. Splice Variants of the RTK Family: Their Role in Tumour Progression and Response to Targeted Therapy.
Abou-Fayçal C; Hatat AS; Gazzeri S; Eymin B
Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28208660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]